FDA sees no safety issues with Pfizer HIV drug

Oct 06, 2009

(AP) -- The Food and Drug Administration says an HIV drug from Pfizer appears safe for expanded use in patients who have not taken other drugs to combat the virus.

Selzentry is already approved as a secondary option for HIV patients who are not responding to other antiviral drugs. Now the company is asking the FDA to approve the drug as a first-choice treatment.

FDA scientists appeared to favor the new use in briefing documents posted online Tuesday.

One review says "no new safety signals were identified in association" with the drug.

On Thursday, the will ask a panel of outside experts to vote on Selzentry's safety and effectiveness. The agency usually follows the group's advice, though it is not required to do so.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: WHO: Millions of Ebola vaccine doses ready in 2015

add to favorites email to friend print save as pdf

Related Stories

FDA approves antiretroviral drug

Aug 07, 2007

The U.S. Food and Drug Administration has approved the antiretroviral drug maraviroc for use in adult human immunodeficiency virus patients.

FDA questions safety of Glaxo kidney cancer drug

Oct 01, 2009

(AP) -- Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease.

FDA weighs approval of psychiatric drugs for kids

Jun 05, 2009

(AP) -- Three blockbuster psychiatric drugs currently approved for adults also appear to work in adolescents, though federal health officials have concerns about exposing younger patients to the drugs' side effects.

FDA: New warning needed for Chantix

Feb 03, 2008

The U.S. Food and Drug Administration Friday called for increased awareness of the health risks of the smoking cessation drug varenicline.

FDA panel backs Schering-Plough cancer drug

Oct 05, 2009

(AP) -- Federal health advisers voted 6-4 on Monday that the potential benefits of a Schering-Plough drug outweigh its toxic risks as a treatment for late-stage skin cancer.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

5 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0